Table 1.
Biological and clinicopathological features of CLL patients.
| Total number of patients | 88 |
|---|---|
| Patients' sex (male/female) | 62/26 |
| Median (range) | |
| Age (years) | 70 (50–90) |
| OS (months) | 42 (4–120) |
| White blood cells (×106/mL) | 32,250 (8500–96,900) |
| Lymphocytes (×106/mL) | 23,050 (5300–69,430) |
| CD38 expression (mean optical intensity of staining) | 7.7 (0.10–59.2) |
| Early apoptosis index (55/88 patients) | 4.7 (0.01–54.8) |
| Number of patients (%) | |
| Binet stage | |
| A | 50 (56.8%) |
| B | 16 (18.2%) |
| C | 22 (25.0%) |
| Rai stage | |
| 0 | 16 (18.2%) |
| I | 27 (30.7%) |
| II | 24 (27.3%) |
| III | 4 (4.5%) |
| IV | 17 (19.3%) |
| Risk group | |
| Low | 16 (18.2%) |
| Intermediate | 51 (58.0%) |
| High | 21 (23.9%) |
| Serum LDH concentration | |
| Normal | 60 (68.2%) |
| Elevated | 28 (31.8%) |
| CD38 expression status | |
| Negative | 73 (83.0%) |
| Positive | 15 (17.0%) |
| IGHV mutational status | |
| Mutated | 45 (51.1%) |
| Unmutated | 43 (48.9%) |
CLL: chronic lymphocytic leukemia; OS: overall survival; LDH: lactate dehydrogenase; IGHV: immunoglobulin heavy chain variable region.